BioSpace News Archive

ROSALIND, a leader in extracting meaningful insights from diverse pools of life science data, today announced the commercial launch of its new solution for single cell data analysis.

Avinger, Inc. (NASDAQ:AVGR), commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced that it will release its financial results for the fourth quarter and full year 2020 after the close of trading on Thursday, March 11, 2021. The Company will host a conference call beginning at 1:30 pm PT/4:30 pm ET.

entrotech life sciences, inc., an organization focused on helping healthcare professionals save lives, is expanding its suite of PrevahexCHX Antimicrobial Dressings to include a transparent securement dressing for central venous access devices (CVAD), as well as a new-and-improved version of its peripheral IV (PIV) securement dressing.

Walgreens Boots Alliance, Inc. will release its fiscal 2021 second quarter earnings results at 7 a.m. Eastern time, Wednesday, March 31, 2021 followed by a one-hour conference call with WBA management beginning at 8:30 a.m. Eastern time.

Multimedia Plus, a training and communications technology company, released its fourth COVID-19 impact survey measuring the effects on pressing technology, training, and spending priorities in the retail and hospitality industries.

Neogen Corporation announced that long-serving G. Bruce Papesh has retired from Neogen’s Board of Directors.

Orbus Therapeutics Inc., a private, late-stage biopharmaceutical company focused on the development and commercialization of therapies that treat rare diseases, today announced a positive outcome of the pre-planned interim analysis for futility in its Phase 3 STELLAR clinical study of eflornithine in patients

RefleXion Medical, a therapeutic oncology company pioneering the use of biology-guided radiotherapy * for all stages of cancer, announced the successful completion of a $40 million extension to its Series D financing, which combined with $110 million raised in 2020, brings the total Series D financing to $150 million.

“The Nasdaq is the premier stock exchange for biotechnology companies, and we believe that this is an opportune time for Cardiol to formally apply for an uplisting of our common shares.

. This is part of our plan to obtain the capital needed to effectively accelerate and execute our developmental activities and continue to advance our portfolio of platforms with unique mechanisms of action for the immune-oncology market from discovery to the clinic.”